Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Management of Febrile Neutropaenia: ESMO Clinical Practice Guidelines

Published in 2016 – Ann Oncol (2016) 27 (suppl 5): v111-v118 
Authors: J. Klastersky, J. de Naurois, K. Rolston, B. Rapoport, G. Maschmeyer, M. Aapro and J. Herrstedt

Febrile neutropaenia is the development of fever, often with other signs of infection, in a patient with neutropaenia, an abnormally low number of neutrophil granulocytes in the blood. Despite major advances in prevention and treatment, febrile neutropaenia is associated with the intensity of chemotherapy and remains one of the most frequent and serious complications of cancer chemotherapy. The updated ESMO Clinical Practice Guidelines include key recommendations for the assessment, risk assessment and management of febrile neutropaenia including patient education and local policies.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.